TQ Course | Clinical Potpourri – Off-Label Medication Use in Optometric Practice (Scottsdale 2021) by Optometric Education Consultants | Feb 11, 2021 | TQ Courses | 0 comments HiddenDate (Hidden) MM slash DD slash YYYY 1. Which organization is responsible for the approval of prescription drugs?* A - FDA B - USDA C - FTC D - FEMA 2. Use of a medication to treat a condition that is not included under FDA-approval is known as what?* A - Illegal B - Off-label use C - Supplementation D - Apothecary-recommended 3. _____________ is the study of how a drug affects the body* A - Pharmacokinetics B - Phrenology C - Pharmacodynamics D - Iridology 4. Fourth-generation fluoroquinolones are FDA-approved for what ocular condition?* A - Bacterial conjunctivitis B - Epidemic keratoconjunctivitis C - Acute angle closure glaucoma D - Myokymia 5. What medication used to treat neovascular retinal disorders and retinal edema was referred to as the crown-prince of ophthalmic off-label use?* A - Bevacizumab (Avastin) B - Omega-6 supplements C - Flintstones chewable multi-vitamins D - Refresh Plus 6. Which off-label uses of topical azithromycin (AzaSite 1%) were discussed?* A - Bacterial conjunctivitis B - Ptosis C - Cystoid macular edema D - Dry-eye related blepharitis 7. Ganciclovir (Zirgan 0.15%) has shown promise as an off-label treatment of what ocular condition?* A - Bacterial corneal ulcer B - Epidemic keratoconjunctivitis C - Severe dry eye syndrome D - Reduction in ischemic injury due to retinal vein occlusion 8. Difluprednate (Durezol 0.05%) is FDA-approved for which ophthalmic condition?* A - Pterygium B - Filamentary keratitis C - Post-surgical inflammation D - Iritis secondary to systemic inflammatory condition 9. What micronutrient was the focus of the Graves’ disease supplementation (GRASS) trial?* A - Tryptophan B - Omega -6 C - Calcium D - Selenium 100 µg BID 10. L-lysine 500mg BID has been suggested to hamper the activity of arginine and decrease the severity of __________________* A - Migraine headaches B - Allergic rhinitis C - Herpes simplex virus D - Myokymia 11. ________________ belongs to a class of medications known as antimycobaterials and has also shown promise in the treatment of chronic, non-resolving CSC?* A - Rimfampin B - Toprimate C - Ibuprofen D - Fexofenadine 12. Doxycycline has been studied in the treatment of what following ophthalmic conditions? Recurrent corneal erosions (RCE)* A - Recurrent corneal erosions (RCE) B - Meibomian gland dysfunction (MGD) C - Dry eye syndrome (DES) D - All of the Above 13. Migraine management has been studied using which of the following topical medications?* A - Dorzolamide B - Timolol 0.5% C - Prednisolone acetate D - Lifitigrast 14. Dorzolamide + Timolol used as adjuvant therapy was found to be effective in which ophthalmic diagnosis?* A - Convergence insufficiency B - Ptosis C - Macular edema related to retina vein occlusion and exudative AMD D - Anisocoria 15. High-dosage atorvastatin has been suggested to have a positive effect in the management of what ophthalmic condition?* A - Atrophic age-related macular degeneration B - Recurrent corneal erosion C - Chronic uveitis D - Angle-closure glaucoma 16. Apraclonodine (Iopidine 1%) is used off-label in the differential diagnosis of what neuro-ophthalmic condition?* A - Syphilis B - Cat scratch fever C - Mild traumatic brain injury D - Horner’s syndrome 17. Topical corticosteroids demonstrate a strong anti-inflammatory component that can be effectively utilized in the treatment of what ophthalmic condition?* A - Retinal Pigmented Epithelial Dysfunction B - Moderate to severe dry-eye syndrome C - Fuch’s dystrophy D - Age-related macular degeneration 18. Prostaglandin analogues can be used to mitigate corneal edema by decreasing IOP in what corneal condition?* A - EBMD B - Superficial punctate keratitis C - Fuch’s dystrophy D - Both A and B 19. Chronic, non-resolving central serous chorioretinopathy has shown a positive therapeutic response when treated with what class of oral medications?* A - Mineralocorticoid antagonists B - Protein supplements C - AREDS2 formulations D - Beta-blockers 20. Cyclosporine (Restais 0.05%) has a number of off-label uses including:* A - Atopic keratoconjunctivitis B - Corneal graft-host rejection C - Post-surgical dryness D - All of the Above Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Clinical Potpourri – Off-Label Medication Use in Optometric Practice | TQ Credit*After 4/15/2021, pricing will increase to $30. Price: (Past 60 Days) Clinical Potpourri – Off-Label Medication Use in Optometric Practice | TQ Credit Price: This course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30.Retake Discount Price: (Past 60 Days) Retake Discount Price: Payment Method*Please note, the charge on your card statement will appear from WeyesGeyes, not Optometric Education Consultants. WeyesGeyes is the LLC that Optometric Education Consultants does business under.Credit Card American ExpressDiscoverMasterCardVisaSupported Credit Cards: American Express, Discover, MasterCard, Visa Card Number Card Number Expiration Date Expiration Date Security Code Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
